# A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

> clinical trial · VERIFIED · 2026-07-20

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Renal Cell Carcinoma

- Company: Merck Sharp & Dohme LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07227402

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.